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Background: Acute respiratory tract infections (RTIs) are the most common reason to seek medical care,
with many patients receiving inappropriate antibiotics. Novel testing approaches to identify aetiology at
the point-of-care are required to accurately guide antibiotic treatment.
Objective: To assess the diagnostic accuracy of biomarker combinations to rapidly differentiate between
acute bacterial or viral RTI aetiology.
Data sources: MEDLINE, Embase and Web of Science databases were searched to February 2021.
Study eligibility criteria: Diagnostic accuracy studies comparing accuracy of point-of-care and rapid
diagnostic tests in primary or secondary care, consisting of biomarker combinations, to identify bacterial
or viral aetiology of RTI.
Methods: Risk of bias was assessed using the QUADAS-2 tool. Sensitivity and specificity of tests reported
by more than one study were meta-analysed using a random effects model.
Results: Twenty observational studies (3514 patients) were identified. Eighteen were judged at high risk
of bias. For bacterial aetiologies, sensitivity ranged from 61% to 100% and specificity from 18% to 96%. For
viral aetiologies, sensitivity ranged from 59% to 97% and specificity from 74% to 100%. Studies evaluating
two commercial tests were meta-analysed. For ImmunoXpert, the summary sensitivity and specificity
were 85% (95% CI 75%e91%, k ¼ 4) and 86% (95% CI 73%e93%, k ¼ 4) for bacterial infections, and 90% (95%
CI 79%e96%, k ¼ 3) and 92% (95% CI 83%e96%, k ¼ 3) for viral infections, respectively. FebriDx had pooled
sensitivity and specificity of 84% (95% CI 75%e90%, k ¼ 4) and 93% (95% CI 90%e95%, k ¼ 4) for bacterial
infections, and 87% (95% CI 72%e95%; k ¼ 4) and 82% (95% CI 66%e86%, k ¼ 4) for viral infections,
respectively.
Conclusion: Combinations of biomarkers show potential clinical utility in discriminating the aetiology of
RTIs. However, the limitations in the evidence base, due to a high proportion of studies with high risk of
bias, preclude firm conclusions. Future research should be in primary care and evaluate patient outcomes
and cost-effectiveness with experimental study designs.
Clinical trial: PROSPERO registration number: CRD42020178973. Henry C. Carlton, Clin Microbiol Infect
2021;▪:1
© 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology
and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).edical School, University of
rlton).
r Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).
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tic prescribing: a systematicIntroduction
Antimicrobial resistance is a major worldwide health issue and
is driven, in part, by inappropriate antibiotic use [1e4]. In Europe,of Clinical Microbiology and Infectious Diseases. This is an open access article under
arker combination tests to differentiate acute bacterial from viral
review, Clinical Microbiology and Infection, https://doi.org/10.1016/
H.C. Carlton et al. / Clinical Microbiology and Infection xxx (xxxx) xxx2acute respiratory tract infections (RTIs) are the most common
reason for antibiotic prescription [5,6]. Previous studies suggest
that 38%e66% of antibiotics prescribed for RTIs are inappropriate
and in English primary care, more than 60% of all inappropriate
antibiotic prescriptions are related to RTIs or conditions of the ears,
nose and throat [7e9]. Although the causes of inappropriate pre-
scription are multifactorial, a key aspect is diagnostic uncertainty
[10e14]. Current testing approaches to guide prescription do not
provide the prompt diagnostic accuracy needed to sufficiently
balance patient health with antibiotic stewardship [15,16].
Many approaches to identify an infectious aetiology are not
applicable to a point-of-care setting. Traditional culture-based ap-
proaches and mass spectrometry are not portable to the bed-side,
have varied diagnostic accuracy and are restricted to cultivatable
bacteria [17,18]. Although PCR tests are being developed with
decreased turnaround times (e.g. for coronavirus disease 2019) [19],
important drawbacks of these tests include low pathogen detection
rates of 20% in adults with respiratory symptoms and in some set-
tings, colonization of non-pathogenic respiratory tract biota occurs
in over 50% of instances [20e24]. Difficulty in differentiating non-
pathogenic microbes is evident in all pathogen-focused approachesFig. 1. PRISMA study
Please cite this article as: Carlton HC et al., Novel point-of-care biom
respiratory tract infections to guide antibiotic prescribing: a systematic
j.cmi.2021.05.018and is complicated by diverse commensal bacteria and disputed
pathogenic roles of viruses [25e28]. Rapid antigen detection testing
is better suited to a point-of-care setting, but variable and sub-
optimal sensitivity restricts their use for routine diagnostics
[29e31]. Ultimately, no viable testing approach exists to accurately
or reliably discriminate RTI aetiology at the point-of-care.
Delayed diagnosis and treatment of bacterial infections can
directly affect patient outcomes. Withholding antibiotics because of
missed or delayed diagnosis may occur in 24%e40% of bacterial in-
fections in secondary care [15,32e34], and is associated with poorer
clinical outcomes, longer hospitalization and increased disease
incidence [35e39]. The overuse of antibiotics has its own implica-
tions, with antibacterial resistance threatening key medical pro-
cedures. In the USA, almost half of post-surgical and nearly one-
quarter of post-chemotherapy infections were caused by bacteria
resistant to standard prophylactic antibiotics and a further 10% drop
in antibiotic efficacy could potentially result in an additional 2000
deaths a year [40]. Consequently, early discrimination of acute RTI
aetiology has both short-term and long-term benefits for patient
outcomes, and novel point-of-care diagnostic approaches are
necessitated.flow diagram.
arker combination tests to differentiate acute bacterial from viral
review, Clinical Microbiology and Infection, https://doi.org/10.1016/
Table 1
Main characteristics of included studies
Test Biomarkersa Age groupb Number of participants Test accuracy comparison(s) Target condition Reference standard Study design Reference
ImmunoXpert TRAIL, IP-10, and
CRP
Adults 218 Bacterial n ¼ 43
Viral n ¼ 109
Other n ¼ 66
Bacterial from non-bacterial
and viral from non-viral
LRTI Expert panel Cohort Shani 2019 [78]
Paediatrics 657 Viral n ¼ 465
Not-viral n ¼ 192
Viral from non-viral RTI Expert panel Cohort Mencaroni 2019 [71]
Adults and
paediatrics
216 Bacterial/bacterial-viral n ¼ 112
Viral n ¼ 104
Bacterial/bacterialeviral from
viral




161 Bacterial/bacterial-viral n ¼ 88
Viral n ¼ 36
Other n ¼ 37
Bacterial/bacterial-viral from
viral
LRTI Expert panel Cohort Stein 2018 [84]
NR 114 Bacterial n ¼ 63
Viral n ¼ 51
Bacterial versus viral Pneumonia
(unspecified)
Expert panel Nested caseecontrol Mastboim 2019 [86]
NR 302 Bacterial n ¼ 61
Viral n ¼ 241
Bacterial versus viral URTI Expert panel Nested caseecontrol Oved 2017 [87])
FebriDX CRP and MxA Adults 47 Bacterial n ¼ 8
Viral n ¼ 35
Non-infectious n ¼ 4
Bacterial from viral and non-
infectious and viral from
bacterial and non-infectious
RTI Clinical algorithm Cohort Karim 2020 [80]
Adults 54 Bacterial/bacterial-viral n ¼ 20
Viral n ¼ 10
Healthy n ¼ 24
Bacterial/bacterialeviral from
viral/healthy
RTI Clinical algorithm Caseecontrol Sambursky 2015 [77]
Adults and
paediatrics
205 Bacterial n ¼ 25
Viral n ¼ 53
Not bacterial or viral n ¼ 127




Cohort Self 2017 [82]
Adults and
paediatrics
220 Bacterial/bacterialeviral n ¼ 34
Viral n ¼ 124
Other n ¼ 62
Bacterial from non-bacterial
and viral from non-viral
URTI Clinical algorithm
with clinician override
Cohort Shapiro 2018 [83]
NR 111 Viral n ¼ 69
Not-viral n ¼ 42
Viral from non-viral RTI Diagnostic microbiological
investigation
Cohort Beard 2019 [85]
Other tests IL-5, IL-6, and IFN-g
or CRP, IL-6, and IL-
27
Adults 104 Pneumococcal n ¼ 48
Bacterialeviral n ¼ 39
Viral n ¼ 17
Pneumococcal/bacterialeviral
from viral
CAP Clinical algorithm Nested caseecontrol Burgmeijer 2019 [75]
CRP and PCT Adults 25 Bacterial/bacterialeH1N1 n ¼ 16





Cohort Ingram 2010 [79]
CRP and neopterin Adults 198 Bacterial n ¼ 105
Bacterialeviral n ¼ 12
Viral n ¼ 81
Bacterial/bacterialeviral from
viral
RTI Clinical algorithm Nested caseecontrol Rainer 2009 [76]
CRP and MPV or
neutrophil and
lymphocyte counts
Paediatrics 52 Bacterial n ¼ 31
Viral n ¼ 21
Bacterial versus viral Pneumonia
(unspecified)
Clinical algorithm Nested caseecontrol Bekdas 2014 [68]
IL-27, PCT and WBC Paediatrics 188 Bacterial n ¼ 52
Viral n ¼ 136





bacterial-viral n ¼ 19
Viral/viral-malarial n ¼ 32
Malarial n ¼ 1
Healthy control n ¼ 16
Bacterial from viral/malarial Pneumonia
(unspecified)
Clinical algorithm Nested caseecontrol Gillette 2021 [74]
CRP, PCT, WBC and
ESR
Paediatrics 55 Pneumococcal n ¼ 25
Pneumococcal-viral n ¼ 13












Paediatrics 80 Bacterial n ¼ 23
Viral n ¼ 30
Malarial n ¼ 27
Bacterial from viral/malarial




Clinical algorithm Nested caseecontrol Valim 2016 [72]
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respiratory tract infections to guide antibiotic prescribing: a systematic
j.cmi.2021.05.018The application of proteomic methodology to RTI diagnostics is
a significant development. Bacterial and viral aetiologies in RTIs
have measurable differences in host-response, allowing these bio-
markers to be surrogate markers of infection aetiology [41,42]. C-
reactive protein (CRP) and procalcitonin (PCT) increase more
extensively in bacterial than in non-bacterial RTIs and, when used
to guide treatment, meta-analyses of experimental research have
shown significant reductions in antibiotic prescription compared
with normal practice [43e46]. However, lone biomarkers have
limitations as CRP has insufficient diagnostic accuracy, disputed
correlation with bacterial load and can produce drastic increases in
response to some viruses while the diagnostic accuracy of PCT has
been shown to vary significantly [41,47e51]. Recent approaches
have attempted to increase diagnostic accuracy through combining
multiple biomarkers.
This study aims to assess the validity of testing multiple bio-
markers, at the point-of-care, to identify bacterial or viral aetiology
in patients with acute RTI.
Materials and methods
We followed recommended methods for systematic review
[52,53] and reported in accordance with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses Diagnostic Test
Accuracy criteria 2018 (see Supplementary material, Table S1) [54].
A protocol was pre-registered [55].
Eligibility criteria
Our review included diagnostic accuracy studies, reporting on
point-of-care and rapid diagnostic tests consisting of more-than-
one biomarker to identify bacterial or viral aetiology, in the gen-
eral population presenting to primary or secondary care with acute
RTI symptoms. Tests could be compared to any reference standard.
Literature search
We searched without language or date restriction in the MED-
LINE, Embase andWeb of Science databases up until February 2021.
The search strategy combined terms for ‘respiratory tract in-
fections’, ‘point-of-care tests/rapid test or combination tests’ and
‘biomarkers’ with a diagnostic test accuracy and systematic review
study design filter (see Supplementary material, Table S2) [56,57].
To help validate these filters, a MEDLINE search was piloted with
and without the filters, with the difference set screened. As no
relevant articles were identified, we were satisfied that addition of
the filter would not compromise sensitivity. Additional records
were identified by screening relevant systematic reviews identified
by the search.
Study selection
Study selection at both abstract and full-text stage was carried
out independently by two investigators (HC and ME). Abstract
screening was conducted using Rayyan [58] and full-paper
screening decisions were recorded in a custom-made Microsoft
ACCESS database. Discrepancies were resolved through discussion or
referral to third reviewer (JS). We contacted study authors to
request further information if articles appeared relevant but did not
fulfil an inclusion criterion.
Data extraction
Data were extracted from each eligible study using a piloted,
pre-defined form built into a custom-made Microsoft ACCESSarker combination tests to differentiate acute bacterial from viral
review, Clinical Microbiology and Infection, https://doi.org/10.1016/
H.C. Carlton et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 5database by one author (HC) and checked by another (ME), with
discrepancies resolved through discussion or referral to a third
reviewer (JS). Data extraction consisted of: study characteristics,
patient characteristics, reference standard details, index test details
and accuracy outcomes.
Risk of bias assessment
The Quality Assessment of Diagnostic Accuracy Studies tool-2
(QUADAS-2) was used to assess methodological quality [59].
QUADAS-2 consists of four key domains: patient selection, index
test, reference standard, and flow and timing. Risk of bias was
assessed in all four domains while concerns over applicability were
assessed in the first three. Domains were judged as low, unclear or
high based on the answers to the signalling questions and judge-
ments were checked by another author and our clinical advisor
(PM). Graphical representation was produced through REVMAN
(version 5.4).
Data handling and analysis
Index tests were classified based on the aetiology, bacterial or
viral, that they aimed to identify. Negative results included inde-
terminate, other infection aetiology or non-infectious cause. All
tests identifying the same aetiology were compared with forest
plots of sensitivity and specificity, using the ‘meta’ package for R
(version 3.6.3) [60,61] Positive predictive values and negative
predictive values were illustrated in a hypothetical population of
1000 acute RTI patients presenting to primary and secondary care
with defined infection aetiology prevalence [62,63]. Receiver
operating characteristics plots were produced, grouping all index
tests identifying the same aetiology, using MetaDTA [64]. Meta-
analysis was restricted to index tests reported by more-than-one
study. We presented the data graphically in forest plots with
summary estimates for sensitivity and specificity, based on the
random effects bivariate binomial model of Chu & Cole with no
covariates, using METADTA [64,65].
Results
Study inclusion
Our electronic searches identified 3436 records (Fig. 1). Of the
2349 unique records, 2243 records were excluded based on ab-
stract screening and 106 underwent full-text review. Of these, 86
were excluded (see Fig. 1 for exclusion reasons) and 20 fulfilled the
inclusion criteria, including a total of 3424 patients. Two systematic
reviews were reviewed for relevant citations with three potentially
relevant studies found that had already been identified by ourFig. 2. Proportions of risk of bias and applic
Please cite this article as: Carlton HC et al., Novel point-of-care biom
respiratory tract infections to guide antibiotic prescribing: a systematic
j.cmi.2021.05.018electronic search [66,67]. Ten studies, reporting on two different
tests, were eligible for meta-analysis.Study characteristics
All identified studies were set in a secondary care environment
(Table 1, see Supplementary material, Table S3). Included age
groups were children only [68e74], adults only [75e80], mixed ] or
not reported [85e87]. Three studies focused specifically on upper
RTIs [82,83,87], two on lower RTIs [78,84] and seven studies
included patients with both upper and lower RTIs
[69,71,76,77,80,81,85]. The remaining eight studies included pa-
tients with pneumoniadcommunity-acquired [70,75,79] or un-
specified [68,72e74,86]. Sample sizes ranged from 25 to 657. There
were six studies with reference standards classified as expert panel,
defined as aetiology decided by more than one clinician's judge-
ment of patient presentation (see Supplementary material,
Table S4) [71,78,81,84,86,87]. Eight studies had reference standards
classified as clinical algorithm, where determination was based
upon an algorithm of clinical signs, symptoms or investigations
with [82,83] or without [68,72,74e77,80] clinician override. Diag-
nostic microbiological investigation as a reference standard was
defined as determination through a targeted- or multiplex-
approach microbiological investigation and was used in four
studies [70,73,79,85]. Only one study used a reference standard of
radiological investigation, which was defined as determination
based on radiological findings [69].
Six studies investigated the accuracy of ImmunoXpert
[71,78,81,84,86,87], which combines CRP, interferon-g-induced
protein 10 and tumour necrosis factor-related apoptosis-inducing
ligand, returning results in 100minutes. Three used a cohort design
[71,78,84], which made it possible to determine the accuracy of the
test in distinguishing bacterial from non-bacterial infections and
viral from non-viral infections among a cohort of patients with
similar symptoms. Three were nested caseecontrol studies
[81,86,87], a study design that creates a sub-cohort of patients with
an exposure of interest from a fully enumerated cohort. In these
three, index tests were assessed at differentiating bacterial infec-
tion cases from viral infection controls and vice versa. One of these
studies [81] classified mixed bacterial-viral infections as bacterial,
so we were only able to evaluate the diagnostic accuracy for bac-
terial aetiology, and a second [87] excluded participants with
indeterminate index test results, artificially inflating the diagnostic
accuracy.
Five studies investigated the accuracy of FebriDx [77,80,82,83,85],
which consists of CRP and myxovirus resistance protein-1 and
returns results in 10 minutes. Four used a cohort design
[80,82,83,85], with one study only reporting accuracy for viral
aetiological testing [85]. The fifth study used a caseecontrol designability concerns judgment by domain.
arker combination tests to differentiate acute bacterial from viral
review, Clinical Microbiology and Infection, https://doi.org/10.1016/
Fig. 3. Summary of risk of bias and applicability concerns judgment by study.
H.C. Carlton et al. / Clinical Microbiology and Infection xxx (xxxx) xxx6with an additional group of healthy participants [77], this allowed
analysis of the index test to distinguish bacterial from viral and
healthy participants as well as viral from bacterial and healthy
participants.Please cite this article as: Carlton HC et al., Novel point-of-care biom
respiratory tract infections to guide antibiotic prescribing: a systematic
j.cmi.2021.05.018The remaining nine studies each reported unique combinations
of biomarkers (Table 1), all using a nested caseecontrol design
[68e70,72e76], bar one with a cohort design [79]. Two studies
[68,69] had populations that allowed for comparison betweenarker combination tests to differentiate acute bacterial from viral
review, Clinical Microbiology and Infection, https://doi.org/10.1016/
H.C. Carlton et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 7groups of patients with bacterial and viral classification while a
third was limited to bacterial accuracy data as mixed bacterial in-
fections were classified as bacterial [76]. Four studies identified
pathogen-specific infections, allowing comparisons of: pneumo-
coccal and mixed bacterial-viral against viral [75], pneumococcal
and mixed pneumococcal-viral against viral [70], bacterial and
mixed bacterialeinfluenza A virus subtype H1N1 against influenza
Avirus subtype H1N1 [79], andMycoplasma pneumonia [73] against
respiratory syncytial virus. The remaining studies incorporated a
malarial group to distinguish bacterial and viral aetiology from
[72,74], with one also adding a healthy control group [74].Quality of included studies
Risk of bias was judged per test but reported per study as no
differences in risk of bias were found within tests of a study (Figs. 2
and 3, see Supplementary material, Table S5). All but three of the
included studies displayed at least one domainwith unclear or high
risk of bias [80,82,83]. Patient selection bias was the most common
reason for the high-risk judgement, in 12 studies with non-cohort
designs [68e70,72e76,81,86,87]. In the index test domain, nine
studies reported high risk of bias where thresholds were not pre-Fig. 4. Diagnostic performance of index tests to identify bacterial aetiology. Abbreviations
protein; ESR, erythrocyte sedimentation rate; FN, false negatives; FP, false positives; GCSF, g
interferon-g-induced protein 10; LRTI, lower respiratory tract infection; MMP-9, matrix me
NGAL, neutrophil gelatinase-associated lipocalin; NPV, negative predictive value; PAL, phe
thyroxine-binding globulin; TIMP-1, tissue inhibitor of metalloproteinase-1; TN, true negativ
URTI, upper respiratory tract infection; WBC, white blood cell count.
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respiratory tract infections to guide antibiotic prescribing: a systematic
j.cmi.2021.05.018specified [68e70,72e76,79]. Regarding the reference standard
domain, two studies [68,69] were considered at high risk of
misclassification bias while three were considered at unclear risk of
incorporation bias with poorly defined ‘laboratory’ parameters
[78,84,86]. Within the flow and timing domain, five were judged to
be at high risk of bias [70,78,84e87] because of inappropriate
participant exclusions and one because children and adults
received different reference standards [84]. Fifteen studies were
judged high concern over their applicability of their population
[68e70,72e77,79,81,84e87]. We deemed the populations of these
studies to be not representative of the typical population. We found
only one study [87] that excluded indeterminate index test results
from diagnostic accuracy measures, to have an index test with high
concern over applicability. For this reason, this study was excluded
from meta-analysis. Five studies had a lack of information on the
reference standard and so were classified as high concern over
applicability [69,71,78,85,87].Diagnostic accuracy of biomarker combination tests
Eighteen studies [68e70,72e84,86,87] evaluated 15 different
biomarker combinations for detection of bacterial aetiology (Figs. 4: A-1AT, a-1 antitrypsin; CKMB, creatinine kinase myocardial band; CRP, C-reactive
ranulocyte colony-stimulating factor; IFN-g, interferon-g; IL-18, interleukin-18; IP-10,
talloproteinase-9; MPV, mean platelet volume; MxA, myxovirus resistance protein 1;
nylalanine ammonia-lyase-1; PCT, procalcitonin; RTI, respiratory tract infection; TBG,
es; TP, true positives; TRAIL, tumour necrosis factor-related apoptosis-inducing ligand;
arker combination tests to differentiate acute bacterial from viral
review, Clinical Microbiology and Infection, https://doi.org/10.1016/
Fig. 5. Receiver operating characteristics plot of the diagnostic accuracy of all index
tests identifying bacterial aetiology.
H.C. Carlton et al. / Clinical Microbiology and Infection xxx (xxxx) xxx8and 5, see Supplementary material, Tables S6 and S7). Sensitivity of
100% was reported by two studies, one using CRP and PCT (95% CI
66%e100%) [79] and a second using FebriDx (95% CI 63%e100%)
[80]. Furthermore, these two studies showed the lowest rates of
inappropriate antibiotic withholding in our hypothetical primary
and secondary care populations [79,80]. The combination of CRP,
PCT, white blood cell count and erythrocyte sedimentation rate
produced the lowest sensitivity for bacterial infection with 61%Fig. 6. Diagnostic performance of index tests to identify bacterial aetiology. Abbreviations:
band; CRP, C-reactive protein; FN, false negatives; FP, false positives; IL-18, interleukin-18;
matrix metalloproteinase-9; MPV, mean platelet volume; MxA, myxovirus resistance protei
TBG, thyroxine-binding globulin; TIMP-1, tissue inhibitor of metalloproteinase-1; TN, true
ligand; URTI, upper respiratory tract infection; WBC, white blood cell count.
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j.cmi.2021.05.018(95% CI 44%e76%) [70]. We found the highest specificity to be 96%
(95% CI 87%e100%) for the ImmunoXpert signature [86] and the
lowest was 18% (95% CI 6%e41%) reported in a test consisting of
interleukin-5, interleukin-6 and interferon-g [75]. In our hypo-
thetical populations, this ImmunoXpert study produced the lowest
rates of inappropriately prescribed antibiotics [86].
There were 12 studies [68,69,71e73,78,80,82,83,85e87] using
nine different biomarker combinations, detecting viral aetiology
(Figs. 6 and 7, see Supplementary material, Tables S6 and S8).
Sensitivity ranged from 97% (95% CI 85%e100%), reported for the
FebriDx signature [80], to 59% (95% CI 50%e67%), reported for a
combination of interleukin-27, PCT and white blood cell count [69].
This FebriDx study also showed the lowest rate of inappropriate
viral management in our hypothetical populations [80]. Further-
more, the highest specificity for viral aetiology was 100% (95% CI
74%e100%) and the lowest percentages of patients inappropriately
not treated for viral infection in our hypothetical populations was
reported using FebriDx [80]. Lowest specificity was reported for a
test consisting of a neutrophil: lymphocyte ratio with 74% (95% CI
74%e88%) [68].ImmunoXpert
ImmunoXpert showed a pooled sensitivity of 85% (95% CI 75%e
91%) and specificity of 86% (95% CI 73%e93%) for bacterial aetiology
in 709 participants in four studies (Fig. 8) [78,81,84,86]. The two
studies reporting diagnostic accuracy on lower RTIs showed lower
specificity for bacterial aetiology [78,84]. When testing for viral
aetiology, in 989 participants from three studies [71,78,86], an
overall estimate for sensitivity was 90% (95% CI 79%e96%) and for
specificity 92% (95% CI 83.0%e96%). Greater sensitivity for viral
aetiologywas shown in a generalized RTI population [71] and lower
specificity was shown in a lower RTI population [78].A-1AT, a-1 antitrypsin; a2m, a-2-macroglobulin; CKMB, creatinine kinase myocardial
IP-10, interferon-g-induced protein 10; LRTI, lower respiratory tract infection; MMP-9,
n 1; NPV, negative predictive value; PCT, procalcitonin; RTI, respiratory tract infection;
negatives; TP, true positives; TRAIL, tumour necrosis factor-related apoptosis-inducing
arker combination tests to differentiate acute bacterial from viral
review, Clinical Microbiology and Infection, https://doi.org/10.1016/
Fig. 7. Receiver operating characteristics plot of the diagnostic accuracy of all index
tests identifying viral aetiology.
H.C. Carlton et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 9FebriDx
The FebriDx tool was tested for bacterial aetiology in 598 par-
ticipants from four studies [77,80,82,83] with a pooled sensitivity of
84% (95% CI 75%e90%) and specificity of 93% (95% CI 90%e95%)
(Fig. 9). When testing for viral aetiology, a sensitivity of 87% (95% CI
72%e95%) and a specificity of 82% (95% CI 66%e86%) was calculated
from 583 participants from four studies [80,82,83,85]. Sensitivity
and specificity did not significantly vary when testing in upper RTI
compared to general RTI populations.Positive and negative predictive values in hypothetical populations
The summative estimates for ImmunoXpert and FebriDx were
compared with single biomarkers of CRP (cut-off 72 mg/mL:
sensitivity 75.0%; specificity 82.0%) and PCT (cut-off 0.2 ng/mL:
sensitivity 80.0%; specificity 86.0%) (Table 2) [88,89]. In both pri-
mary and secondary care, FebriDx-guided antibiotic prescriptionFig. 8. Summative diagnostic performance of ImmunoXpert for bacterial
Please cite this article as: Carlton HC et al., Novel point-of-care biom
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j.cmi.2021.05.018would result in the lowest rate of inappropriate prescription with
comparable rates of inappropriate withholding.Discussion
This systematic review demonstrates the potential clinical
utility of a wide range of biomarker combination tests to distin-
guish acute bacterial and viral RTI aetiology. Summative estimates
of two biomarker combinations, ImmunoXpert and FebriDx, out-
performed thewidely used single biomarkers of bacterial aetiology,
CRP and PCT [88,89].
Currently, ImmunoXpert is only feasible in inpatient settings.
Although an iteration with a 25-minute turnaround time is in
development, this is still ill-suited for outpatient settings. In sec-
ondary care it is theorized to reduce antibiotic use by 78%e83% in
two conference abstracts [78,86]. In hypothetical primary and
secondary care populations, ImmunoXpert-guided antibiotic pre-
scription resulted in less inappropriate prescriptions than that of
CRP with lower rates of inappropriate withholding than CRP and
PCT. Reducing inappropriate antibiotic use is important, not only
for efficiency of treatment, but also for preventing the build up of
antibiotic resistance in the community while maintaining low rates
of inappropriate withholding is important in sustaining patient
safety. ImmunoXpert has greater specificity for bacterial infections
than CRP and outperformed single parameters of temperature,
white blood cell count, CRP, PCT and absolute neutrophil count as
well as radiological determination when tested in the same popu-
lation [84,87,88]. However, the evidence base was judged to have a
high overall risk for bias and estimated accuracy measures are
imprecise with wide confidence intervals. Furthermore, a study by
Oved et al. was excluded from meta-analysis [87] because partici-
pants with indeterminate index test results were excluded from
analysis, which has been shown to artificially inflate test accuracy
by up to 20% in similar populations [90,91]. Therefore, after con-
tacting the authors without response, we felt this study could not
be included in our meta-analysis.
FebriDx shows potential clinical utility in both primary and
secondary care settings, with a turnaround time sufficient to be
considered point-of-care in either, and specificity that is superior to
CRP, PCT and ImmunoXpert for bacterial infection [88]. High
specificity is advantageous in outpatient settings where infections
tend to be less severe and reducing antibiotic prescription should
be prioritized. In a small retrospective study in UK primary care,
antibiotic prescriptions were reduced by 80% with no adverse ef-
fects when guided by FebriDx [92]. In our hypothetical inpatientand viral aetiology. RTI, respiratory tract infection; LRTI, lower RTI.
arker combination tests to differentiate acute bacterial from viral
review, Clinical Microbiology and Infection, https://doi.org/10.1016/
Table 2
Comparison of biomarker-guided antibiotic prescription in hypothetical primary and secondary care





withheld antibiotics (95% CI)
Primary care (bacterial
aetiology prevalence 21%) [86]
CRP (cut-off 72 mg/mL) [88] 14.2 5.2
PCT (cut-off 0.2 ng/mL) [89] 11.1 4.2
ImmunoXpert 11.1 (5.5e21.3) 3.2 (1.9e5.2)
FebriDX 5.5 (4.0e7.9) 3.4 (2.1e5.2)
Secondary care (bacterial
aetiology prevalence 24%) [87]
CRP (cut-off 72mg/mL) [88] 13.7 6.0
PCT (cut-off 0.2ng/mL) [89] 10.6 4.8
ImmunoXpert 10.7 (5.3e20.5) 3.6 (2.2e6.0)
FebriDX 5.3 (3.8e7.6) 3.8 (2.4e6.0)
Abbreviations: CRP, C-reactive protein; PCT, procalcitonin.
Fig. 9. Summative diagnostic performance of FebriDx for bacterial and viral aetiology. RTI, respiratory tract infection; URTI, upper RTI.
H.C. Carlton et al. / Clinical Microbiology and Infection xxx (xxxx) xxx10and outpatient populations, FebriDx outperformed CRP, PCT and
ImmunoXpert with the lowest rate in appropriate antibiotic use
and comparable antibiotic withholding to ImmunoXpert. Although
the evidence base is small, with only five studies identified,
research was found to be of higher quality. Four studies were peer-
reviewed articles and three were judged at low risk of bias.
The remaining biomarker combinations had unspecified turn-
around times. Without means of rapid assessment, these combi-
nations are incompatible with outpatient point-of-care testing.
Standard hospital testing would return results in a feasible time for
inpatients. Effective inpatient point-of-care testing requires high
sensitivity for bacterial aetiology or high specificity for viral aeti-
ology as infections tend to be more severe. However, these com-
binations showed mostly comparable or inferior diagnostic
performance to standalone biomarkers, diminishing their potential
clinical utility.
To the best of our knowledge, this is the first review focusing on
the diagnostic accuracy of biomarker combinations identifying
bacterial or viral acute RTI aetiology. A review by Thomas et al. [66]
was restricted to a paediatric population with pneumonia and
included index tests of biomarkers in isolation. As a result of
differing inclusion criteria, we felt that our review focused on a gap
in the current literature. Although we validated the use of the
search filter, the possibility that a relevant publication was missed
is a limitation. Additionally, our review excluded clinical prediction
rules that combined biomarkers and clinical signs. Clinical features,
particularly pyrexia [83], have a significant impact on pre-test
probability as clinician assessment will influence decision-making
alongside their understanding of a test result. All included studies
had inclusion criteria specifying pyrexia and a further reviewwould
be warranted to explore the diagnostic accuracy of clinical features
combined with biomarkers.Please cite this article as: Carlton HC et al., Novel point-of-care biom
respiratory tract infections to guide antibiotic prescribing: a systematic
j.cmi.2021.05.018Limitations in the evidence base precluded robust interpreta-
tion and conclusions. The sparsity of data meant that summary
estimates were relatively imprecise. Varying populations, target
conditions, reference standards and study designs likely contrib-
uted to wide confidence intervals. The use of clinically relevant
predictive values was limited by varying, and often high, preva-
lence of infection aetiologies in the study populations. We
attempted to remedy this by using hypothetical populations with
defined prevalence, but findings should be confirmed, particularly
in outpatient studies. The validity and applicability of included
studies was also a limitation with an overall high risk of bias
observed in 18 studies and 16 studies having high population
applicability concern. Caseecontrol and nested caseecontrol study
designs have limited implications for clinical practice. Reducing the
study population to clearly defined viral or bacterial infections
makes it impossible to determine if tests are still accurate in a
realistic population of possible viral, bacterial, fungal and parasitic
infection, or other non-infectious cause. However, in a nested
caseecontrol study, cases and controls are selected from the same
underlying cohort, which makes it less biased than a caseecontrol
study where cases and controls are recruited separately. Further-
more, the absence of a reference standard dictated a reliance on
imperfect references. To be useful, such tests need to demonstrate a
difference in outcomes, rather than just accuracy compared with a
potentially inaccurate diagnostic standard. As a result of the
numerous limitations in the evidence base we exercised caution in
interpreting results and making recommendations.
Future research should aim to expand the current evidence base.
Included studies were almost exclusively conducted in secondary
care environments, limiting applicability to outpatients where
point-of-care testing is arguably most required. Moreover, all
studies included in this review were observational. This meant keyarker combination tests to differentiate acute bacterial from viral
review, Clinical Microbiology and Infection, https://doi.org/10.1016/
H.C. Carlton et al. / Clinical Microbiology and Infection xxx (xxxx) xxx 11secondary outcomes, that affect the adoption of testing, such as
antibiotic reduction, adverse effects and cost-effectiveness analysis
were limited. Future research should be experimental, in the form
of randomized controlled trials, and aim to collect this information.
This review is also not exhaustive of all possible candidate bio-
markers that exhibit discriminatory ability. Expansion of the evi-
dence bank will aid the discovery and evaluation of optimum
combinations of biomarkers to determine acute RTI aetiology. Ul-
timately, no testing approach will be a panacea and future work
must identify the optimal clinical context for each approach,
factoring in cost, patient outcomes and antibiotic stewardship.
Conclusion
A wide variety of biomarker combinations show potential clin-
ical utility. However, current research is overshadowed with bias
and is insufficient to make recommendations, especially in primary
care where the evidence is entirely lacking. The FebriDx and
ImmunoXpert detection tools show significant potential to
discriminate aetiology and reduce unnecessary antibiotic pre-
scription. Future research should aim to grow the evidence base in
primary care and experimentally evaluate patient outcomes and
cost-effectiveness.
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